MedMira Receives New Annual Standing Order for OTC Rapid HIV Tests from Hong Kong Distributor Reaches Long-Term Agreement to Answer Growing Market Demand HALIFAX, May 12 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has received a monthly standing order for the next year from Goodman Medical Supplies Ltd, its Hong Kong distributor, for its MiraCare(TM) Rapid HIV Test (MiraCare(TM)), as part of a three year distribution agreement. MiraCare(TM), an over-the-counter (OTC) rapid HIV test, is distributed to pharmacies in Hong Kong and Macao, in the People's Republic of China. Since the launch of MiraCare(TM) at the end of January 2005, MedMira has been shipping 5,000 tests monthly to Goodman, to fulfill a standing order based on their initial sales estimates. The market success experienced to date has resulted in MedMira entering into a new three year distribution agreement with Goodman for the Hong Kong and Macao regions. The new annual standing order, which begins in July 2005, increases the monthly shipment to 20,000 units. "MiraCare(TM) is our highest profile product, and it is quickly becoming one of MedMira's market leaders," said Stephen Sham, chairman and chief executive officer of MedMira. "Goodman's extensive experience in medical supply distribution has been clearly demonstrated by its timely, and very successful, expansion into new market verticals for our product." Collen Chan, managing director of Goodman Medical Supplies Ltd. said, "The general public is extremely receptive to the convenience of purchasing such a high quality, easy-to-use rapid HIV test that provides immediate results. It is becoming obvious that people want to learn their HIV status privately." Chan continued, "MedMira's OTC rapid HIV test is a proven success in our distribution network. Our success to date will serve as the basis for expansion of the MiraCare(TM) product line in our sales territory." MiraCare(TM) is sold as a complete test package with all components required for an individual to conduct the test quickly; with results showing in just three minutes. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout the Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail:

Copyright